Skip to main content Accessibility help
  • Cited by 1
  • Print publication year: 2014
  • Online publication date: December 2014

1 - Introduction


1. R. W. Carrell, D. A. Lomas. Conformational disease. Lancet 1997; 350: 134–8.
2. V. H. Cornejo, C. Hetz. The unfolded protein response in Alzheimer’s disease. Semin Immunopathol 2013; 35: 277–92.
3. D. A. Nijholt, L. De Kimpe, H. L. Elfrink, J. J. Hoozemans, W. Scheper. Removing protein aggregates: the role of proteolysis in neurodegeneration. Curr Med Chem 2011; 18: 2459–76.
4. G. G. Kovacs, G. Botond, H. Budka. Protein coding of neurodegenerative dementias: the neuropathological basis of biomarker diagnostics. Acta Neuropathol 2010; 119: 389–408.
5. J. L. Guo, V. M. Lee. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med 2014; 20: 130–8.
6. H. Braak, E. Braak. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239–59.
7. H. Braak, K. Del Tredici, U. Rub, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24: 197–211.
8. J. Brettschneider, K. Del Tredici, D. J. Irwin, et al. Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathol 2014; 127: 423–39.
9. J. Brettschneider, K. Del Tredici, J. B. Toledo, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013; 74: 20–38.
10. D. R. Thal, U. Rub, M. Orantes, H. Braak. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791–800.
11. E. Kuusisto, T. Kauppinen, I. Alafuzoff. Use of p62/SQSTM1 antibodies for neuropathological diagnosis. Neuropathol Appl Neurobiol 2008; 34: 169–80.
12. C. Bancher, C. Brunner, H. Lassmann, et al. Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer’s disease. Brain Res 1989; 477: 90–9.
13. E. Kuusisto, L. Parkkinen, I. Alafuzoff. Morphogenesis of Lewy bodies: dissimilar incorporation of α-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol 2003; 62: 1241–53.
14. M. Neumann, E. Bentmann, D. Dormann, et al. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain 2011; 134: 2595–609.
15. J. Woulfe, D. A. Gray, I. R. Mackenzie. FUS-immunoreactive intranuclear inclusions in neurodegenerative disease. Brain Pathol 2010; 20: 589–97.
16. G. G. Kovacs, H. Budka. Current concepts of neuropathological diagnostics in practice: neurodegenerative diseases. Clin Neuropathol 2010; 29: 271–88.